- GlobeNewswire•4 days agoRexahn Pharmaceuticals Doses First Patient in a Phase IIa Trial of Supinoxin™ in Patients with Metastatic Triple Negative Breast Cancer
ROCKVILLE, Md., Feb. 23, 2017-- Rexahn Pharmaceuticals, Inc., today announced that is has begun enrolling patients into a Phase IIa clinical study of Supinoxin™ in metastatic triple negative breast cancer. ...
- Accesswire•21 days ago
ROCKVILLE, MD / ACCESSWIRE / February 6, 2017 / Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, ...
- GlobeNewswire•last monthRexahn Pharmaceuticals Presents an Update of the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Pancreatic Cancer at the American Society of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium
ROCKVILLE, Md., Jan. 20, 2017-- Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing next generation targeted therapeutics for the treatment of cancer, today announced an ...
RNN : Summary for Rexahn Pharmaceuticals, Inc. - Yahoo Finance
Rexahn Pharmaceuticals, Inc. (RNN)
NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.23 - 0.25|
|52 Week Range||0.13 - 0.39|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-4.17|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|